pharmaphorum

DECEMBER 4, 2020

Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.

Vaccination 119

Vaccination Vaccine Bacterium Protein 119

XTalks

APRIL 15, 2025

XTALKS WEBINAR: Leveraging AI in Clinical Development to Innovate with Greater Confidence Live and On-Demand: Tuesday, June 3, 2025 , at 10am EDT (4pm CEST / EU-Central) Register for this free webinar to learn how AI-powered technology can uncover potential study design risks by identifying areas of patient burden and complexity.

FDA Approval 66

FDA Approval Bacteria DNA Bacterium 66

pharmaphorum

MARCH 2, 2022

diff causes nearly 30,000 deaths each year in the US, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections. diff since Sanofi ended development of its candidate in 2017, ahead of Valneva whose VLA84 has been shelved after phase 2 while it looks for a development partner.

Vaccination 52

Vaccination Vaccine Trials Bacterium 52

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. Notably, sales from their COVID-19 drug Actemra (tocilizumab) dropped significantly by 22 percent.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JUNE 2, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion to be paid upon the achievement of certain paediatric clinical development milestones. The bacterium Streptococcus pneumoniae causes pneumococcal disease. GSK will account for the transaction as a business combination.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

MAY 31, 2022

A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion to be paid upon the achievement of certain paediatric clinical development milestones. The bacterium Streptococcus pneumoniae causes pneumococcal disease. CAGR: Compound Annual Growth Rate; **CER: Constant Exchange Rate.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52